VivoSeq
Ophthalmology

Age-Related Macular Degeneration

202

Pipeline Programs↗

70

Active Trials↗

76

Companies Involved↗

Age-Related Macular Degeneration is a highly competitive landscape with 202 programs across 76 companies. The most active players are Chengdu Origen Biotechnology Co., Ltd., AiViva BioPharma, Inc., Jiangsu T-Mab Biopharma Co.,Ltd. 14 therapies are approved with 36 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

42/100

Mech. Concentration

12/100

Completion Rate

77/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chengdu Origen Biotechnology Co., Ltd.

2 programs

Phase 1A

AiViva BioPharma, Inc.

1 program

Phase 1J

Jiangsu T-Mab Biopharma Co.,Ltd

1 program

Phase 1P

Potentia Pharmaceuticals, Inc.

1 program

Phase 1Q

Quark Pharmaceuticals

1 program

Phase 1P

Paloma Pharmaceuticals, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

85%

Small molecule

181 of 213 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody209%Protein / enzyme52%Gene therapy42%Peptide2<1%Cell therapy1<1%

Small molecule leads; the ring shows all 213 classified programs, each share of the total. Modality classified for 100% of 238 pipeline programs.

Analysis

Trial Status

358

clinical trials

Completed200 · 56%
Terminated45 · 13%
Recruiting30 · 8%
Active, not recruiting30 · 8%
Unknown status27 · 8%
Withdrawn14 · 4%
Other12 · 3%

Clinical Trials

Trial Activity

358 trials

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Recruiting·Roche logoRoche·N/A·NCT06439576·1,000 enrolled
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Recruiting·AAdverum Biotechnologies, Inc.·Phase 3·NCT06856577·284 enrolled
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Recruiting·44D Molecular Therapeutics·Phase 3·NCT07064759·480 enrolled
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Recruiting·Astellas logoAstellas·Phase 1·NCT03178149·42 enrolled
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Recruiting·OOcugenix Corporation·Phase 1·NCT05904691·19 enrolled
Eggs and Age-related Macular Degeneration (EggsAMD) Study.
Recruiting·—·Phase 1·NCT07021027·20 enrolled
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Recruiting·IInnostellar Biotherapeutics Co.,Ltd·Phase 3·NCT07317934·332 enrolled
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Recruiting·EEyebioKorea, Inc.·Phase 2·NCT06487039·50 enrolled
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Recruiting·Roche logoRoche·Phase 1·NCT06961370·132 enrolled
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Recruiting·KKing's College Hospital NHS Trust·Phase 3·NCT04663750·210 enrolled
EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).
Recruiting·IInsel Gruppe AG, University Hospital Bern·N/A·NCT07434713·50 enrolled
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Recruiting·AAdverum Biotechnologies, Inc.·Phase 3·NCT07482176·284 enrolled
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Recruiting·EEyestem Research Pvt. Ltd.·Phase 1/2·NCT06394232·54 enrolled
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Recruiting·AAlcon Research·Phase 1/2·NCT05769153·140 enrolled
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Recruiting·SShanghai Refreshgene Technology Co., Ltd.·Phase 1/2·NCT06141460·48 enrolled
Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)